Want to see HK:2190 full AI Analyst Report?
Top Page
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
(2190)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$24.00
▲(8.30% Upside)
Action:Downgraded
Date:08/06/26
Overall score is driven primarily by the strong financial recovery (high margins, improving profitability, and low leverage), which supports a solid fundamental profile. This is tempered by weak technicals (price below major moving averages with negative MACD and low RSI) and a valuation that appears reasonable but not particularly cheap given the P/E and modest dividend yield.
Positive Factors
Profitability inflection
The sharp improvement in profitability, combined with high gross margins and year-over-year revenue growth, indicates stronger earnings capacity from the company’s device portfolio. If maintained, this recovery can provide more resources for commercial expansion and product development over the next several quarters.
Negative Factors
Historical earnings volatility
Multiple years of losses show that the recent profit improvement has not yet been demonstrated across a full operating cycle. This history lowers confidence in the durability of current earnings and means future results remain more sensitive to execution than those of a consistently profitable business.
Read all positive and negative factors
Positive Factors
Negative Factors
Profitability inflection
The sharp improvement in profitability, combined with high gross margins and year-over-year revenue growth, indicates stronger earnings capacity from the company’s device portfolio. If maintained, this recovery can provide more resources for commercial expansion and product development over the next several quarters.
Read all positive factors
Zylox-Tonbridge Medical Technology Co., Ltd. Class H (2190) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$7.57B
Dividend Yield1.7%
Average Volume (3M)609.48K
Price to Earnings (P/E)19.8
Beta (1Y)0.68
Revenue Growth39.30%
EPS Growth109.37%
CountryHK
Employees1,214
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.95
Shares Outstanding336,350,740
10 Day Avg. Volume1,210,145
30 Day Avg. Volume609,476
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)2.08
Price to Sales (P/S)6.35
P/FCF Ratio24.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$28.42Price Target Upside28.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)1.08
Revenue Forecast (FY)HK$1.50B
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Zylox-Tonbridge Medical Technology Co., Ltd. is a global medical device firm specializing in neurovascular and peripheral vascular interventional technologies. Their comprehensive product line for treating ischemic stroke includes the ThromBite Cl...
How the Company Makes Money
Zylox-Tonbridge primarily makes money by selling interventional medical devices to hospitals and other healthcare providers, generating revenue from the commercialization of its proprietary product portfolio used in minimally invasive vascular pro...
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
88
Very Positive
Cash Flow
67
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.21B | 1.06B | 782.48M | 527.75M | 334.09M | 177.91M |
| Gross Profit | 883.70M | 762.92M | 559.89M | 384.99M | 252.67M | 131.88M |
| EBITDA | 328.12M | 231.92M | 65.30M | -41.60M | -86.56M | -208.49M |
| Net Income | 302.83M | 244.37M | 100.26M | -78.73M | -113.56M | -199.69M |
Balance Sheet | ||||||
| Total Assets | 3.73B | 3.58B | 3.45B | 3.38B | 3.25B | 3.25B |
| Cash, Cash Equivalents and Short-Term Investments | 1.48B | 1.73B | 1.28B | 1.51B | 1.86B | 2.93B |
| Total Debt | 143.12M | 63.67M | 90.91M | 55.88M | 14.00M | 9.40M |
| Total Liabilities | 733.89M | 343.98M | 351.56M | 328.32M | 159.54M | 103.61M |
| Stockholders Equity | 3.00B | 3.23B | 3.10B | 3.05B | 3.09B | 3.14B |
Cash Flow | ||||||
| Free Cash Flow | 171.33M | 268.72M | -17.26M | -92.48M | -236.60M | -205.80M |
| Operating Cash Flow | 230.60M | 377.07M | 174.08M | 98.44M | -91.32M | -116.21M |
| Investing Cash Flow | -27.23M | -46.54M | -801.36M | -206.24M | -95.05M | -1.33B |
| Financing Cash Flow | -85.26M | -168.64M | -41.98M | -11.46M | -30.26M | 2.81B |
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Technical Analysis
Neutral
22.16
Price Trends
19.86
Positive
20.36
Positive
21.87
Negative
Market Momentum
0.56
Negative
55.23
Neutral
47.84
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2190, the sentiment is Neutral. The current price of 22.16 is above the 20-day moving average (MA) of 20.77, above the 50-day MA of 19.86, and above the 200-day MA of 21.87, indicating a neutral trend. The MACD of 0.56 indicates Negative momentum. The RSI at 55.23 is Neutral, neither overbought nor oversold. The STOCH value of 47.84 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:2190.
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$5.56B | 12.63 | 13.24% | 2.36% | 16.15% | 31.89% | |
70 Outperform | HK$5.57B | 19.72 | 9.20% | 4.95% | 10.27% | 79.65% | |
66 Neutral | HK$7.57B | 19.83 | 9.72% | 1.70% | 39.30% | 109.37% | |
59 Neutral | HK$5.98B | 92.65 | 1.72% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$3.43B | -20.55 | -7.65% | ― | 21.23% | 36.89% | |
45 Neutral | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― |
* Healthcare Sector Average
HK:2190
Zylox-Tonbridge Medical Technology Co., Ltd. Class H
21.16
-4.88
-18.75%
HK:0853
MicroPort Scientific
6.08
-8.33
-57.81%
HK:9996
Peijia Medical Ltd.
5.08
-2.77
-35.29%
HK:1302
LifeTech Scientific Corporation
1.38
-0.62
-31.00%
HK:1789
AK Medical Holdings Ltd.
5.00
-0.77
-13.39%
HK:1858
Beijing Chunlizhengda Medical Instruments Co., Ltd. Class H
8.13
-8.91
-52.32%
Zylox-Tonbridge Medical Technology Co., Ltd. Class H Corporate Events
Zylox-Tonbridge Delivers Strong Interim Growth on High-Margin Vascular Devices
Aug 20, 2026
Zylox-Tonbridge reported strong interim results for the six months ended June 30, 2026, with revenue rising 31.1% year-on-year to RMB632.0 million and profit for the period jumping 47.8% to RMB179.1 million. Gross profit margin improved from 71.2%...
Zylox-Tonbridge Schedules Board Meeting to Approve Interim Results
Aug 10, 2026
Zylox-Tonbridge Medical Technology Co., Ltd., a Hong Kong-listed Chinese medical technology company, is governed by a board comprising executive, non-executive and independent non-executive directors, reflecting a standard corporate governance str...
Zylox-Tonbridge Updates H Share Buyback, Signals Confidence in Long-Term Prospects
Jun 15, 2026
Zylox-Tonbridge Medical Technology has provided an update on its ongoing H share repurchase programme aimed at enhancing market capitalisation management and creating long-term value for shareholders. Over the past three months, the company has sp...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.